Arqule Inc. Securities Litigation

If you purchased a significant amount of shares of ArQule, Inc. (NASDAQ: ARQL), you have certain options. Investors should contact us.

 

Lawsuit Overview

Defendant:ArQule, Inc.
Date Filed:January 2nd, 2020
Sector:Health Care
Industry:Major Pharmaceuticals
Class Start Date:December 9th, 2019
Class End Date:January 2nd, 2020

According to the Complaint, ArQule, Inc. is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases.

This action stems from a proposed transaction announced on December 9, 2019, pursuant to which ArQule, Inc. will be acquired by affiliates of Merck & Co., Inc.

On December 6, 2019, ArQule's Board of Directorscaused the Company to enter into an agreement and plan of merger with Merck Sharp & Dohme Corp.

On December 17, 2019, Defendants filed a Solicitation/Recommendation Statement with the United States Securities and Exchange Commission in connection with the Proposed Transaction. The Complaint alleges that the Solicitation Statement omits material information with respect to the Proposed Transaction, which renders the Solicitation Statement false and misleading.

Sign up for free to create a personalized portfolio with tracking and e-mail alerts for ArQule, Inc.

 
First Identified Complaint

George Assad, et al. v. Arqule Inc., et al.

Date Filed:January 2nd, 2020
Class Period Start:December 9th, 2019
Class Period End:January 2nd, 2020
First Identified Complaint Filings
#Document TitleFiling Date